Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
personalized polyclonal TCR-T cell therapy
- Development stage
- Unknown
- Lead developer
- Guangzhou FineImmune Biotechnology
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Personalized polyclonal TCR-T cell therapy is an autologous, genetically modified T-cell therapy being developed by Guangzhou FineImmune Biotechnology for the treatment of advanced solid tumors. The therapy utilizes the company's proprietary HAP platform to identify naturally occurring T-cell receptors (TCRs) that target a patient's unique tumor neoantigens (tumor-specific antigens). Using the GSOP and CMP platforms, autologous T cells are engineered to express these specific TCRs and expanded in a polyclonal fashion, allowing the final product to target multiple neoantigens simultaneously. This multi-target approach is designed to overcome tumor heterogeneity and reduce the likelihood of immune escape. The therapy is currently undergoing Phase I clinical evaluation at the Affiliated Tumor Hospital of Sun Yat-sen University in Guangzhou, China.
- Other names
- personalized neoantigen-specific TCR-T cell therapypersonalized polyclonal TCR-T
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on personalized polyclonal TCR-T cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on personalized polyclonal TCR-T cell therapy.